Prostate Cancer Clinical Trial

Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients

Summary

The purpose of this research study is to learn about: 1) How standard radiation treatment to prostate (primary radiotherapy) or the pelvis after prostatectomy (postoperative radiotherapy) may cause changes in MRI and PET imaging traits that might be used in the future to predict response. 2) Comparison of such MRI and PET imaging traits with the number of circulating tumor cells (CTCs) present in the blood prior to treatment and the changes in these counts after treatment. 3) How MRI and PET imaging characteristics and changes are related to the expression of genes in the cancer tissue obtained before treatment from prostate biopsy or a prior prostatectomy before treatment. 4) How the response of prostate cancer treatment relates to the imaging and CTC changes.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Pathologic confirmation of prostate cancer.
Any T-stage.

By imaging or clinical criteria, any patient with disease staging of N0/N1 and M0/M1.

Patients with metastatic disease are encouraged to participate.
Any Gleason Score will be eligible.

Androgen deprivation therapy (ADT) is at the discretion of the treating physician, but must be declared as none, short-term, long-term, or extended prior to enrollment. The length is calculated from the LHRH (agonist injection). If ADT is planned (based on treating physician preference), the following restrictions apply:

Short term ADT is defined as ≤ 7 months;
Long term ADT is defined as > 7 months and ≤ 36 months;
Extended ADT is defined as >36 months (e.g., M1 patients).
Prostate-specific antigen (PSA) ≤100 ng/mL within (+/-) 4 months of signing of consent. If PSA was above 100 and drops to <100 with antibiotics, this is acceptable for enrollment.
No previous pelvic radiotherapy.
The ability to understand and the willingness to sign a written informed consent document
Zubrod performance status ≤ 2 (Karnofsky or ECOG performance status may be used to estimate Zubrod):
Age ≥ 30 at signing of consent.
Subjects must be planned to receive radiation therapy or to undergo prostatectomy.
Subjects treated primarily with RT are recommended to have had an MUFgBx prior to radiation treatment.

Study is for people with:

Prostate Cancer

Estimated Enrollment:

144

Study ID:

NCT02997709

Recruitment Status:

Recruiting

Sponsor:

University of Miami

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Miami
Miami Florida, 33136, United States More Info
Pavel Noa Hechevarria
Contact
305-243-1036
[email protected]
Alan Pollack, MD, Ph.D.
Principal Investigator
Matthew Abramowitz, MD
Principal Investigator
Radka Stoyanova, Ph.D.
Principal Investigator
Alan Dal Pra, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

144

Study ID:

NCT02997709

Recruitment Status:

Recruiting

Sponsor:


University of Miami

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.